128 related articles for article (PubMed ID: 38857264)
41. A Structural Landscape of Neutralizing Antibodies Against SARS-CoV-2 Receptor Binding Domain.
Niu L; Wittrock KN; Clabaugh GC; Srivastava V; Cho MW
Front Immunol; 2021; 12():647934. PubMed ID: 33995366
[TBL] [Abstract][Full Text] [Related]
42. Recognition of Variants of Concern by Antibodies and T Cells Induced by a SARS-CoV-2 Inactivated Vaccine.
Melo-González F; Soto JA; González LA; Fernández J; Duarte LF; Schultz BM; Gálvez NMS; Pacheco GA; Ríos M; Vázquez Y; Rivera-Pérez D; Moreno-Tapia D; Iturriaga C; Vallejos OP; Berríos-Rojas RV; Hoppe-Elsholz G; Urzúa M; Bruneau N; Fasce RA; Mora J; Grifoni A; Sette A; Weiskopf D; Zeng G; Meng W; González-Aramundiz JV; González PA; Abarca K; Ramírez E; Kalergis AM; Bueno SM
Front Immunol; 2021; 12():747830. PubMed ID: 34858404
[TBL] [Abstract][Full Text] [Related]
43. A bispecific antibody exhibits broad neutralization against SARS-CoV-2 Omicron variants XBB.1.16, BQ.1.1 and sarbecoviruses.
Wang Y; Hao A; Ji P; Ma Y; Zhang Z; Chen J; Mao Q; Xiong X; Rehati P; Wang Y; Wang Y; Wen Y; Lu L; Chen Z; Zhao J; Wu F; Huang J; Sun L
Nat Commun; 2024 Jun; 15(1):5127. PubMed ID: 38879565
[TBL] [Abstract][Full Text] [Related]
44. Response and Duration of Serum Anti-SARS-CoV-2 Antibodies After Inactivated Vaccination Within 160 Days.
Xu QY; Xue JH; Xiao Y; Jia ZJ; Wu MJ; Liu YY; Li WL; Liang XM; Yang TC
Front Immunol; 2021; 12():786554. PubMed ID: 35003104
[TBL] [Abstract][Full Text] [Related]
45. Broadly neutralizing antibodies against sarbecoviruses generated by immunization of macaques with an AS03-adjuvanted COVID-19 vaccine.
Feng Y; Yuan M; Powers JM; Hu M; Munt JE; Arunachalam PS; Leist SR; Bellusci L; Kim J; Sprouse KR; Adams LE; Sundaramurthy S; Zhu X; Shirreff LM; Mallory ML; Scobey TD; Moreno A; O'Hagan DT; Kleanthous H; Villinger FJ; Veesler D; King NP; Suthar MS; Khurana S; Baric RS; Wilson IA; Pulendran B
Sci Transl Med; 2023 May; 15(695):eadg7404. PubMed ID: 37163615
[TBL] [Abstract][Full Text] [Related]
46. Characterization of a Broadly Neutralizing Monoclonal Antibody against SARS-CoV-2 Variants.
Zakir TS; Meng T; Carmen LCP; Chu JJH; Lin RTP; Prabakaran M
Viruses; 2022 Jan; 14(2):. PubMed ID: 35215823
[TBL] [Abstract][Full Text] [Related]
47. Anti-SARS-CoV-2 Immunoglobulin Isotypes, and Neutralization Activity Against Viral Variants, According to BNT162b2-Vaccination and Infection History.
Tarkowski M; de Jager W; Schiuma M; Covizzi A; Lai A; Gabrieli A; Corbellino M; Bergna A; Ventura CD; Galli M; Riva A; Antinori S
Front Immunol; 2021; 12():793191. PubMed ID: 34975897
[TBL] [Abstract][Full Text] [Related]
48. Limited Variation between SARS-CoV-2-Infected Individuals in Domain Specificity and Relative Potency of the Antibody Response against the Spike Glycoprotein.
Van Ert HA; Bohan DW; Rogers K; Fili M; Rojas Chávez RA; Qing E; Han C; Dempewolf S; Hu G; Schwery N; Sevcik K; Ruggio N; Boyt D; Pentella MA; Gallagher T; Jackson JB; Merrill AE; Knudson CM; Brown GD; Maury W; Haim H
Microbiol Spectr; 2022 Feb; 10(1):e0267621. PubMed ID: 35080430
[TBL] [Abstract][Full Text] [Related]
49. Identification of a highly conserved neutralizing epitope within the RBD region of diverse SARS-CoV-2 variants.
Wang Y; Yan A; Song D; Duan M; Dong C; Chen J; Jiang Z; Gao Y; Rao M; Feng J; Zhang Z; Qi R; Ma X; Liu H; Yu B; Wang Q; Zong M; Jiao J; Xing P; Pan R; Li D; Xiao J; Sun J; Li Y; Zhang L; Shen Z; Sun B; Zhao Y; Zhang L; Dai J; Zhao J; Wang L; Dou C; Liu Z; Zhao J
Nat Commun; 2024 Jan; 15(1):842. PubMed ID: 38287016
[TBL] [Abstract][Full Text] [Related]
50. Novel Monoclonal Antibodies and Recombined Antibodies Against Variant SARS-CoV-2.
Xie J; Ding C; He J; Zhang Y; Ni S; Zhang X; Chen Q; Wang J; Huang L; He H; Li W; Ma H; Jin T; Zhang S; Gao Y
Front Immunol; 2021; 12():715464. PubMed ID: 34539645
[TBL] [Abstract][Full Text] [Related]
51. Repeated Omicron exposures override ancestral SARS-CoV-2 immune imprinting.
Yisimayi A; Song W; Wang J; Jian F; Yu Y; Chen X; Xu Y; Yang S; Niu X; Xiao T; Wang J; Zhao L; Sun H; An R; Zhang N; Wang Y; Wang P; Yu L; Lv Z; Gu Q; Shao F; Jin R; Shen Z; Xie XS; Wang Y; Cao Y
Nature; 2024 Jan; 625(7993):148-156. PubMed ID: 37993710
[TBL] [Abstract][Full Text] [Related]
52. Memory B cell repertoire from triple vaccinees against diverse SARS-CoV-2 variants.
Wang K; Jia Z; Bao L; Wang L; Cao L; Chi H; Hu Y; Li Q; Zhou Y; Jiang Y; Zhu Q; Deng Y; Liu P; Wang N; Wang L; Liu M; Li Y; Zhu B; Fan K; Fu W; Yang P; Pei X; Cui Z; Qin L; Ge P; Wu J; Liu S; Chen Y; Huang W; Wang Q; Qin CF; Wang Y; Qin C; Wang X
Nature; 2022 Mar; 603(7903):919-925. PubMed ID: 35090164
[TBL] [Abstract][Full Text] [Related]
53. Non-Glycosylated SARS-CoV-2 Omicron BA.5 Receptor Binding Domain (RBD) with a Native-like Conformation Induces a Robust Immune Response with Potent Neutralization in a Mouse Model.
Wongnak R; Brindha S; Oba M; Yoshizue T; Islam MD; Islam MM; Takemae H; Mizutani T; Kuroda Y
Molecules; 2024 Jun; 29(11):. PubMed ID: 38893549
[TBL] [Abstract][Full Text] [Related]
54. Safety and immunogenicity against ancestral, Delta and Omicron virus variants following a booster dose of an inactivated whole-virus COVID-19 vaccine (VLA2001): Interim analysis of an open-label extension of the randomized, controlled, phase 3 COV-COMPARE trial.
Taucher C; Lazarus R; Dellago H; Maurer G; Weisova P; Corbic-Ramljak I; Dubischar K; Lilja A; Eder-Lingelbach S; Hochreiter R; Jaramillo JC; Junker H; Krammer M; Pusic P; Querton B; Larcher-Senn J; Hoffmann M; Pöhlmann S; Finn A;
J Infect; 2023 Sep; 87(3):242-254. PubMed ID: 37406777
[TBL] [Abstract][Full Text] [Related]
55. SARS-CoV-2 mRNA vaccine induces robust specific and cross-reactive IgG and unequal neutralizing antibodies in naive and previously infected people.
Narowski TM; Raphel K; Adams LE; Huang J; Vielot NA; Jadi R; de Silva AM; Baric RS; Lafleur JE; Premkumar L
Cell Rep; 2022 Feb; 38(5):110336. PubMed ID: 35090596
[TBL] [Abstract][Full Text] [Related]
56. A highly potent antibody effective against SARS-CoV-2 variants of concern.
Fenwick C; Turelli P; Perez L; Pellaton C; Esteves-Leuenberger L; Farina A; Campos J; Lana E; Fiscalini F; Raclot C; Pojer F; Lau K; Demurtas D; Descatoire M; Joo VS; Foglierini M; Noto A; Abdelnabi R; Foo CS; Vangeel L; Neyts J; Du W; Bosch BJ; Veldman G; Leyssen P; Thiel V; LeGrand R; Lévy Y; Trono D; Pantaleo G
Cell Rep; 2021 Oct; 37(2):109814. PubMed ID: 34599871
[TBL] [Abstract][Full Text] [Related]
57. Comprehensive Overview of Broadly Neutralizing Antibodies against SARS-CoV-2 Variants.
Cui L; Li T; Xue W; Zhang S; Wang H; Liu H; Gu Y; Xia N; Li S
Viruses; 2024 Jun; 16(6):. PubMed ID: 38932192
[TBL] [Abstract][Full Text] [Related]
58. Decreased and Heterogeneous Neutralizing Antibody Responses Against RBD of SARS-CoV-2 Variants After mRNA Vaccination.
Hernández-Luis P; Aguilar R; Pelegrin-Pérez J; Ruiz-Olalla G; García-Basteiro AL; Tortajada M; Moncunill G; Dobaño C; Angulo A; Engel P
Front Immunol; 2022; 13():816389. PubMed ID: 35464418
[TBL] [Abstract][Full Text] [Related]
59. SARS-CoV-2 Spike Protein Stabilized in the Closed State Induces Potent Neutralizing Responses.
Carnell GW; Ciazynska KA; Wells DA; Xiong X; Aguinam ET; McLaughlin SH; Mallery D; Ebrahimi S; Ceron-Gutierrez L; Asbach B; Einhauser S; Wagner R; James LC; Doffinger R; Heeney JL; Briggs JAG
J Virol; 2021 Jul; 95(15):e0020321. PubMed ID: 33963055
[TBL] [Abstract][Full Text] [Related]
60. Reduced sensitivity of SARS-CoV-2 variant Delta to antibody neutralization.
Planas D; Veyer D; Baidaliuk A; Staropoli I; Guivel-Benhassine F; Rajah MM; Planchais C; Porrot F; Robillard N; Puech J; Prot M; Gallais F; Gantner P; Velay A; Le Guen J; Kassis-Chikhani N; Edriss D; Belec L; Seve A; Courtellemont L; Péré H; Hocqueloux L; Fafi-Kremer S; Prazuck T; Mouquet H; Bruel T; Simon-Lorière E; Rey FA; Schwartz O
Nature; 2021 Aug; 596(7871):276-280. PubMed ID: 34237773
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
